Maeda Kosen (7821) · FactDropped
Recognition of a ¥36.359 million impairment loss on investment securities
First written in FY2020-Q3. 2 of 7 entries say "Restated". Latest entry: FY2025-H1.
7entries
6years
0from disclosures
How it moved
Same theme, other companies
Recognition of Valuation Losses on Investment Securities and Impairment LossesA theme 283 companies write about · 286 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2026: 35 of 81 companies on the "Worse" side.
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 286 threads.Full recordFilings, disclosures and news, newest first
- FY2025-H1DroppedAnnual report
「Loss on sale of investment securities 29 － Impairment loss on investment securities 1,041 －」
Neither a loss on sale nor an impairment loss on investment securities was recognized during the interim consolidated accounting period, and the impairment loss of ¥1,041 million reported for the same period of the previous year no longer appears. - FY2024-Q2Change from recognition of an impairment loss to recognition of a loss on saleAnnual report
「Loss on sale of investment securities － 29 Impairment loss on investment securities 1,041 －」
Compared with the ¥1,041 million impairment loss on investment securities in the same period of the previous year, no impairment loss was recognized in the cumulative third-quarter period, while a ¥29 million loss on sale of investment securities was recognized. - FY2023-Q2WorsenedAnnual report
「Impairment loss on investment securities 1,041」
An impairment loss on investment securities of ¥1,041 million was recognized because the net asset value of the unlisted shares of Svelte Medical Systems, Inc. had declined significantly. The impairment loss increased substantially from the ¥254 million previously reported. - FY2022-Q2RestatedAnnual report
「Impairment loss on investment securities 254」
The recognition of an impairment loss on investment securities of ¥254 million was also confirmed for the cumulative second-quarter period. - FY2022-Q1Significant increase in impairment loss on investment securitiesAnnual report
「Impairment loss on investment securities 254」
An impairment loss on investment securities of ¥254 million was recognized as an extraordinary loss, an increase from the ¥36 million previously reported. - FY2020RestatedAnnual report
「During the consolidated fiscal year, an impairment loss of ¥36 million was recognized on other securities.」
The recognition of an impairment loss on investment securities of ¥36 million was also confirmed in the full-year results. - FY2020-Q3First statedAnnual report
「Impairment loss on investment securities 36.359」
An impairment loss on investment securities of ¥36.359 million was recognized as an extraordinary loss for the nine-month period of the third quarter of the consolidated fiscal year.